1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,250 | 6,500 | 19:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | WUXI XDC Opens 2.15% Higher w/Plan of Share Buyback of Up to USD100M | 1 | AASTOCKS | ||
| Mo | WUXI XDC (02268): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET SHARE PURCHASE FOR THE SHARE SCHEMES OF THE COMPANY | - | HKEx | ||
| 12.05. | JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO | 2 | AASTOCKS | ||
| 24.04. | WUXI XDC (02268): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | 1 | HKEx | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| 24.04. | WUXI XDC (02268): ANNUAL REPORT 2025 | - | HKEx | ||
| 09.04. | Akari Therapeutics Plc: Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC | 1 | GlobeNewswire (USA) | ||
| 08.04. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.04. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | 1 | HKEx | ||
| 06.04. | Akari Therapeutics slides 21% despite WuXi XDC backing its drug program | 3 | Seeking Alpha | ||
| 06.04. | Akari Therapeutics Partners with WuXi XDC to Accelerate Development of Novel PH1 Payload | 1 | Contract Pharma | ||
| 06.04. | Akari Therapeutics partners with WuXi XDC on ADC development | 2 | Investing.com | ||
| 06.04. | Akari Therapeutics Plc: Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing | 143 | GlobeNewswire (Europe) | TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing... ► Artikel lesen | |
| 31.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 2 | HKEx | ||
| 23.03. | WUXI XDC (02268): INSIDE INFORMATION 2025 ANNUAL RESULTS PRESENTATION | - | HKEx | ||
| 23.03. | WUXI XDC (02268): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 13.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 8 | HKEx | ||
| 27.02. | WuXi XDC, Earendil Labs Partner to Accelerate the Development of ADCs | 1 | Contract Pharma | ||
| 27.02. | Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs | 2 | FierceBiotech | ||
| 27.02. | WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform | 390 | PR Newswire | SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization)... ► Artikel lesen | |
| 11.02. | WUXI XDC (02268): MAJOR TRANSACTION IN RELATION TO VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE ... | - | HKEx |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 35,680 | +35,72 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| HCW BIOLOGICS | 2,140 | +101,89 % | HCW Biologics Inc.: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results | MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative... ► Artikel lesen | |
| QIAGEN | 29,910 | +0,66 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| METAVIA | 2,925 | +55,59 % | MetaVia Inc.: MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update | 48 mg Phase 1 Data Demonstrated Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit
Key Milestone... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,520 | +10,54 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| PRAXIS PRECISION MEDICINES | 335,43 | +4,62 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 13,180 | +9,20 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies | Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with all patients ongoing Interim investigator- and patient-reported... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 37,290 | +3,93 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| ERASCA | 11,340 | +9,88 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,865 | +5,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,240 | +4,63 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| EVOTEC | 4,900 | +3,38 % | Evotec rutscht erneut ab - das ist der Grund | Kräftig nach unten geht es am heutigen Mittwoch bei der Aktie von Evotec. Mit Carl Zeiss Meditec gehört sie mit einem Verlust von mehr als acht Prozent zu den zwei größten Verlierern des Tages im Nebenwerte-Index... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,450 | +4,25 % | Beam Therapeutics presents AATD gene therapy trial data at ATS | ||
| APOGEE THERAPEUTICS | 81,83 | +4,55 % | Jefferies raises Apogee Therapeutics stock price target on trial outlook | ||
| CG ONCOLOGY | 64,48 | +1,86 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen |
Das Unternehmen WUXI XDC CAYMAN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,93 % bei einem Aktienkurs von 6,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.